Zynerba Pharmaceuticals ROE 2024

Zynerba Pharmaceuticals Aktienanalyse

What does Zynerba Pharmaceuticals do?

Zynerba Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for patients with severe central nervous system disorders. The company was founded in 2007 and is headquartered in Devon, Pennsylvania, USA. The history of Zynerba Pharmaceuticals dates back to the discovery by Dr. Magid Abou-Gharbia, who led a team of scientists that developed a method for transporting cannabinoids through the blood-brain barrier. This groundbreaking discovery led to the formation of Zynerba Pharmaceuticals with the goal of developing novel cannabinoid-based therapies. Zynerba Pharmaceuticals' business model is based on the development of medical compounds derived from the cannabis plant. These compounds, known as cannabinoids, have the potential to treat a variety of different conditions related to the central nervous system. The company's strategy is to deliver these compounds in the form of transdermal patches to ensure optimal dosage and absorption by the body. Zynerba Pharmaceuticals is divided into different divisions that focus on specific conditions. The company's main division is the development of therapies for epilepsy based on the cannabinoid Zygel. Zygel is a synthetic cannabinoid administered as a transdermal patch and has high bioavailability. The patch is applied to the skin and delivers a precise dosage of Zygel to reduce seizures in patients with various forms of epilepsy. In addition, Zynerba Pharmaceuticals is working on therapies for neuropsychiatric disorders such as Fragile X syndrome, autism spectrum disorders, and schizophrenia. The company has a promising development pipeline and is currently involved in various clinical trials. The company has achieved many milestones and formed important partnerships to support its innovative research and development. In 2019, Zynerba Pharmaceuticals partnered with the Japanese company Daiichi Sankyo to expand its development pipeline. In summary, Zynerba Pharmaceuticals Inc offers a promising business model for the development of therapies for severe central nervous system disorders based on cannabinoids. The company has a promising development pipeline and has already formed important partnerships to support its research and development. Zynerba Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Zynerba Pharmaceuticals's Return on Equity (ROE)

Zynerba Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Zynerba Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Zynerba Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Zynerba Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Zynerba Pharmaceuticals Stock

What is the ROE (Return on Equity) of Zynerba Pharmaceuticals this year?

The ROE of Zynerba Pharmaceuticals this year is -0.76 undefined.

How has the Return on Equity (ROE) of Zynerba Pharmaceuticals developed compared to the previous year?

The ROE of Zynerba Pharmaceuticals has increased by 44.05% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Zynerba Pharmaceuticals?

A high ROE indicates that Zynerba Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Zynerba Pharmaceuticals?

A low ROE can indicate that Zynerba Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Zynerba Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Zynerba Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Zynerba Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Zynerba Pharmaceuticals?

Some factors that can influence Zynerba Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Zynerba Pharmaceuticals pay?

Over the past 12 months, Zynerba Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zynerba Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Zynerba Pharmaceuticals?

The current dividend yield of Zynerba Pharmaceuticals is .

When does Zynerba Pharmaceuticals pay dividends?

Zynerba Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Zynerba Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zynerba Pharmaceuticals located?

Zynerba Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zynerba Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zynerba Pharmaceuticals from 6/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/9/2024.

When did Zynerba Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/9/2024.

What was the dividend of Zynerba Pharmaceuticals in the year 2023?

In the year 2023, Zynerba Pharmaceuticals distributed 0 USD as dividends.

In which currency does Zynerba Pharmaceuticals pay out the dividend?

The dividends of Zynerba Pharmaceuticals are distributed in USD.